Skip to content

A study comparing two steroid injections to compare which gives longer pain relief in patients with tennis elbow

Comparative Efficacy of Triamcinolone Acetonide 40mg and Triamcinolone Hexacetonide 20mg for Symptom-free Interval in Lateral Epicondylitis: A Double blind, Randomized controlled trial. - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096247
Enrollment
84
Registered
2025-10-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention1: Triamcinolone hexacetonide: 20mg of Triamcinolone hexacetonide given intralesionally in Lateral epicondylitis. Injection will be given as a one time dose on Visit 1 after screening and

Sponsors

AELIYA FATIMA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Tenderness on palpation of lateal epicondyle and extensor unit 2. Pain at the effected site on gripping hand dynamometer at any pressure 3.Pain on contraction of wrist extensors using cozens test. 4. Symptoms of greater then 6 weeks duration

Exclusion criteria

Exclusion criteria: 1. History of surgery or trauma to the effected elbow. 2. History of corticosteroid injection in past 6 months. 3. Co-existing systemic conditions like rheumatoid arthritis and other Auto-immune diseases, Uncontrolled diabetes mellitus. 4. Ongoing local or systemic infection. 5. Pregnant or lactating women. 6. History of psychiatric diseases. 7. Any previous drug reaction to corticosteroids.

Design outcomes

Primary

MeasureTime frame
PRIMARY OUTCOME 1.To assess the return or increase in pain on follow up 2.To asses level of pain using VAS 3.To assess level of pain using PRTEE Questionnaire Timepoint: VISIT 1( WEEK -1) VISIT 2( WEEK 1) VISIT 3(WEEK 12) VISIT 4(WEEK 24)

Secondary

MeasureTime frame
1. Grip strength using hand dynamometer measured at visit 2,3 and 4 2. Compare the incidence of adverse effects at visit 3 and 4 Timepoint: VISIT 1( WEEK -1) VISIT 2( WEEK 1) VISIT 3(WEEK 12) VISIT 4(WEEK 24)

Countries

India

Contacts

Public Contactaeliya fatima

ESIC Medical College and Hospital

seethapharmacology@gmail.com6369702539

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026